IOVANCE BIOTHERAPEUTICS, INC. — Director's Dealing 2022

Jun 16, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK: 0001425205
Period of Report: 2022-06-14

Reporting Person: Bellemin Jean-Marc (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-06-14	Common Stock	M	18850	—	Acquired	18850	Direct
2022-06-14	Common Stock	F	9346	$7.73	Disposed	9504	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-06-14	Restricted Stock Units	$	A	18850	Acquired		Common stock (18850)	Direct

Footnotes

F1: This is the first vesting of the restricted stock units issued on June 14, 2021.

F2: Represents common stock owned by the Reporting Person, excluding common stock purchased pursuant to the Issuer's 2020 Employee Stock Purchase Plan.

F3: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units. This is not an open market sale of securities.

F4: Represents common stock remaining after deducting the common stock withheld for taxes.

F5: Represents restricted stock units remaining after deducting the vested shares of common stock and common stock withheld for taxes as set forth in Table I above.

F6: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

F7: Provided the Reporting Person is still employed with the Issuer on December 31, 2022, the remaining restricted stock units shall vest and be settled on such date.